1. Introduction {#sec1-ijms-19-03036}
===============

Augmented airway responsiveness to a wide variety of nonspecific stimuli, called airway hyperresponsiveness (AHR), is a common feature of allergic asthma. A cause of the AHR is hypercontraction of smooth muscle cells of the airways \[[@B1-ijms-19-03036],[@B2-ijms-19-03036],[@B3-ijms-19-03036],[@B4-ijms-19-03036],[@B5-ijms-19-03036]\]. Rapid remission from airway limitation in asthma attack by inhalation of short-acting beta-stimulant also suggests an involvement of increased airway smooth muscle contraction in the airway obstruction. It is thus important for development of asthma therapy to understand the disease-associated alterations of the contractile signaling of airway smooth muscle cells.

Prostaglandin D~2~ (PGD~2~), one of the cyclooxygenase (COX) metabolites, is the major lipid mediator released from mast cells in allergic reaction, and has been suggested to be involved in the pathogenesis of bronchial asthma. An increase in PGD~2~ level in bronchoalveolar lavage (BAL) fluids was demonstrated in experimental asthma models \[[@B6-ijms-19-03036],[@B7-ijms-19-03036]\]. In asthmatic subjects, allergen challenge to the airways caused an increase in PGD~2~ in BAL fluids \[[@B8-ijms-19-03036],[@B9-ijms-19-03036]\]. It has been suggested that PGD~2~ mediates allergic inflammation, including the airway inflammation in asthma. In mice lacking receptors for PGD~2~ (DP~1~ receptors), both airway eosinophilia and upregulation of proinflammatory cytokines in BAL fluids induced by allergen challenge were diminished as compared to wild-type animals \[[@B10-ijms-19-03036]\]. PGD~2~ also caused cytokine release via an activation of a PGD~2~ receptor, CRTH2 (also called as DP~2~ receptor), in Th2 lymphocytes \[[@B11-ijms-19-03036]\].

On the other hand, the functional role of PGD~2~ on airway smooth muscle remains unclear. Application of PGD~2~ to the isolated smooth muscle strips caused contraction in guinea pig trachea \[[@B12-ijms-19-03036]\] and dog bronchus \[[@B13-ijms-19-03036]\]. In contrast, PGD~2~ elicited a relaxation in the murine tracheal smooth muscle precontracted with carbachol \[[@B10-ijms-19-03036]\]. In the present study, to elucidate its role in the development of AHR in asthma, the effect of PGD~2~ on smooth muscle contractility was determined using bronchial rings isolated from mice.

2. Results {#sec2-ijms-19-03036}
==========

2.1. Effects of Prostaglandin D~2~ (PGD~2~) on Bronchial Smooth Muscle (BSM) Function {#sec2dot1-ijms-19-03036}
-------------------------------------------------------------------------------------

The RT-PCR analyses revealed that both DP~1~ and DP~2~ receptors were expressed both in hBSMCs and murine BSMs ([Figure 1](#ijms-19-03036-f001){ref-type="fig"}), indicating that PGD~2~ could directly act on BSM cells. To determine the role of PGD~2~ on the BSM function, its effect on the isometric tension of smooth muscles was examined in BSM tissues isolated from naive control mice. Application of PGD~2~ (10^−9^--10^−5^ M) had no effect on basal tone of the BSM tissues ([Figure 2](#ijms-19-03036-f002){ref-type="fig"}A). However, when the BSMs were precontracted with 30 mM K^+^, application of PGD~2~ caused an enhancement of the contraction induced by high K^+^ depolarization, in a PGD~2~ concentration-dependent manner (10^−6^ and 10^−5^ M: [Figure 2](#ijms-19-03036-f002){ref-type="fig"}B,C).

PGD~2~ has been known to act on G protein-coupled receptors (GPCRs), mainly the PGD~2~ receptor 1 (DP~1~) and 2 (DP~2~). To elucidate receptor(s) responsible for the enhanced contraction induced by PGD~2~, effects of laropiprant (a selective DP~1~ receptor antagonist \[[@B14-ijms-19-03036]\]) and fevipiprant (a selective DP~2~ receptor antagonist \[[@B15-ijms-19-03036]\]) on the PGD~2~-induced augmentation of contraction were tested. As a result, the enhanced contraction induced by PGD~2~ was inhibited by laropiprant (10^−6^ M: [Figure 3](#ijms-19-03036-f003){ref-type="fig"}A,B), whereas fevipiprant (10^−6^ M) had no effect on it ([Figure 3](#ijms-19-03036-f003){ref-type="fig"}C).

2.2. Effects of Prostaglandin D~2~ (PGD~2~) on Cytosolic Ca^2+^ Level in Human Bronchial Smooth Muscle Cells (hBSMCs) {#sec2dot2-ijms-19-03036}
---------------------------------------------------------------------------------------------------------------------

Due to the difficulty in preparing isolated BSM cells with high purity from the mouse tissues, change in cytosolic Ca^2+^ level was measured using commercially available human BSM cells (hBSMCs) in the present study. The hBSMCs were loaded with a green fluorescent Ca^2+^ indicator, Fluo-8 \[[@B16-ijms-19-03036]\]. As shown in [Figure 4](#ijms-19-03036-f004){ref-type="fig"}A,B, in the hBSMCs incubated with Fluo-8/AM, stimulation of the cells with a Ca^2+^ ionophore A23187 (10^−5^ M) caused a marked increase in *F*/*F~0~*, that is, an increase in cytosolic Ca^2+^ concentration, indicating a successful loading of Fluo-8 into the cells. In the Fluo-8-loaded hBSMCs, stimulation of the cells with 30 mM K^+^ caused a slight but distinct increase in cytosolic Ca^2+^ concentration ([Figure 4](#ijms-19-03036-f004){ref-type="fig"}B,C). Interestingly, PGD~2~ had no effect on the K^+^ depolarization-induced increase in cytosolic Ca^2+^ level ([Figure 4](#ijms-19-03036-f004){ref-type="fig"}B,C). PGD~2~ also did not alter the basal cytosolic Ca^2+^ level in the Fluo-8-loaded cells ([Figure 4](#ijms-19-03036-f004){ref-type="fig"}A).

2.3. Activation of RhoA/Rho-Kinase Signaling by Prostaglandin D~2~ (PGD~2~) {#sec2dot3-ijms-19-03036}
---------------------------------------------------------------------------

The results that PGD~2~ caused an augmentation of contraction ([Figure 2](#ijms-19-03036-f002){ref-type="fig"}B,C) under the constant cytosolic Ca^2+^ level ([Figure 4](#ijms-19-03036-f004){ref-type="fig"}) remind us of the Ca^2+^ sensitization of smooth muscle contraction. In smooth muscle cells including airways, activation of a monomeric G-protein, RhoA, causes Ca^2+^ sensitization of the contraction by activating its downstream Rho-kinases \[[@B17-ijms-19-03036],[@B18-ijms-19-03036]\]. To determine whether PGD~2~ activates RhoA protein, the GTP-RhoA pull-down assay was performed in mouse BSMs stimulated by PGD~2~. As previously reported \[[@B19-ijms-19-03036]\], acetylcholine (ACh: 10^−3^ M) stimulation caused an increase in GTP-bound, active form of RhoA protein in the BSMs of mice ([Figure 5](#ijms-19-03036-f005){ref-type="fig"}A). Similarly, as shown in [Figure 5](#ijms-19-03036-f005){ref-type="fig"}A, an increase in the active form of RhoA protein was observed when the BSM tissues were stimulated with 10^−5^ M PGD~2~, the concentration where no contractile response from baseline tone was observed (see above). The tension study also revealed an activation of RhoA/Rho-kinase signaling by PGD~2~: the PGD~2~-induced augmentation of contraction was blocked by Y-27632 (10^−7^ M), a selective inhibitor of Rho-kinases ([Figure 5](#ijms-19-03036-f005){ref-type="fig"}B).

3. Discussion {#sec3-ijms-19-03036}
=============

The current study was carried out to determine the role of prostaglandin D~2~ (PGD~2~) on smooth muscle function of the airways using the bronchial smooth muscles (BSMs) isolated from mice. Although PGD~2~ had no effect on their baseline tension, PGD~2~ significantly augmented the BSM contraction induced by high K^+^ depolarization ([Figure 2](#ijms-19-03036-f002){ref-type="fig"}B,C). The PGD~2~-induced augmentation of contraction was inhibited both by a DP~1~ antagonist, laropiprant, and a Rho-kinase inhibitor, Y-27632 ([Figure 3](#ijms-19-03036-f003){ref-type="fig"} and [Figure 5](#ijms-19-03036-f005){ref-type="fig"}B). Furthermore, PGD~2~ could cause an activation of RhoA protein ([Figure 5](#ijms-19-03036-f005){ref-type="fig"}A). In the high K^+^-depolarized cultured human BSM cells, PGD~2~ caused no further increase in cytosolic Ca^2+^ concentration ([Figure 4](#ijms-19-03036-f004){ref-type="fig"}). These findings suggest that PGD~2~ acts on DP~1~ receptors to cause RhoA/Rho-kinase-mediated Ca^2+^ sensitization of contraction in BSMs.

PGD~2~ is an acidic lipid mediator derived from the metabolism of arachidonic acid by the action of cyclooxygenases and downstream PGD~2~ synthases, and is mainly released from mast cells when activated by antigen stimulation \[[@B20-ijms-19-03036]\]. Allergen challenge to the airways caused an increase in PGD~2~ level in the airways of asthmatics \[[@B8-ijms-19-03036],[@B9-ijms-19-03036]\]. However, the functional role of PGD~2~ on airway smooth muscle has not yet been unified. In tracheal smooth muscle strips isolated from the guinea pigs, PGD~2~ produced a concentration-dependent contraction \[[@B12-ijms-19-03036]\]. Similarly, PGD~2~ caused a contraction in bronchial rings isolated from the dogs \[[@B13-ijms-19-03036]\]. In contrast, PGD~2~, at a concentration of 3 µM, elicited a relaxation in the murine tracheal smooth muscle precontracted with carbachol \[[@B10-ijms-19-03036]\]. Currently, PGD~2~ had no effect on basal tension in BSMs isolated from the mice (see Results section). Differences in the species, region (tracheal versus bronchial smooth muscles), and/or the experimental condition used may be involved in the difference in the PGD~2~ response in smooth muscles of the airways. Thus, note that the current study also contains a certain limitation: cultured human BSM cells (hBSMCs) were used for cytosolic Ca^2+^ measurement whereas functional studies were performed using mouse BSM tissues.

The current RT-PCR analyses showed expression of DP~1~ and DP~2~ receptors in BSM cells ([Figure 1](#ijms-19-03036-f001){ref-type="fig"}), indicating that PGD~2~ could directly act on BSM cells. Although PGD~2~ did not affect the basal tension, it augmented the submaximal contraction induced by 30 mM K^+^ in BSMs isolated from the mice ([Figure 2](#ijms-19-03036-f002){ref-type="fig"}). The augmented contraction induced by PGD~2~ was inhibited by laropiprant ([Figure 3](#ijms-19-03036-f003){ref-type="fig"}), a DP~1~ antagonist \[[@B14-ijms-19-03036]\], but not by fevipiprant (see RESULTS), a DP~2~ antagonist \[[@B15-ijms-19-03036]\]. An involvement of TP receptor in the PGD~2~-mediated contraction has also been suggested \[[@B21-ijms-19-03036]\]. However, PGD~2~ did not increase cytosolic Ca^2+^ in the present study ([Figure 4](#ijms-19-03036-f004){ref-type="fig"}), whereas an induction of contraction with Ca^2+^ mobilization by the TP receptor activation has been demonstrated \[[@B22-ijms-19-03036]\]. In addition, our preliminary study revealed that stimulation of TP receptors with a thromboxane A~2~ (TXA~2~) mimic, U46619, caused a distinct contraction from baseline tension (without K^+^ depolarization) in the mouse BSMs. Pretreatment of BSMs with ozagrel, an inhibitor of TXA~2~ synthase, also did not inhibit the augmented contraction induced by PGD~2~ (data not shown). It is thus unlikely that the TXA~2~/TP receptor is involved in the PGD~2~-mediated response in the mouse BSMs. Thus, an activation of DP~1~ receptors on the BSM cells might be responsible for the synergistic contraction induced by PGD~2~.

Currently, PGD~2~ augmented the contraction induced by high K^+^ depolarization in mouse BSM tissues ([Figure 2](#ijms-19-03036-f002){ref-type="fig"}B,C). In the high K^+^-depolarized cultured hBSMCs, PGD~2~ caused no further increase in cytosolic Ca^2+^ concentration ([Figure 4](#ijms-19-03036-f004){ref-type="fig"}). Collectively, these findings suggest that PGD~2~ augmented the BSM contraction induced by K^+^ depolarization without any increase in cytosolic Ca^2+^ concentration. The observation that PGD~2~ caused an augmentation of contraction under the constant cytosolic Ca^2+^ level reminds us of the Ca^2+^ sensitization of smooth muscle contraction. Indeed, the augmented contraction induced by PGD~2~ was inhibited by a Rho-kinase inhibitor, Y-27632 ([Figure 5](#ijms-19-03036-f005){ref-type="fig"}). In addition, stimulation of the BSMs with PGD~2~ caused an increase in the active form of RhoA, GTP-bound RhoA ([Figure 5](#ijms-19-03036-f005){ref-type="fig"}). The current study for the first time, to our knowledge, demonstrated that PGD~2~ activates the RhoA/Rho-kinase signaling to induce Ca^2+^ sensitization of contraction in the BSMs. Previous studies, including ours, demonstrated that muscarinic receptor stimulation of airway smooth muscle caused both an increase in cytosolic Ca^2+^ concentration and an activation of RhoA/Rho-kinase signaling, resulting in the contraction \[[@B17-ijms-19-03036],[@B23-ijms-19-03036],[@B24-ijms-19-03036]\]. On the other hand, the current study revealed that PGD~2~ did not have the ability to increase cytosolic Ca^2+^ level in the BSMs ([Figure 4](#ijms-19-03036-f004){ref-type="fig"}). This may be a reason that PGD~2~ did not cause any contraction from the baseline tension: the cytosolic Ca^2+^ level at the baseline tension might not have been enough to induce BSM contraction even if the RhoA/Rho-kinase signaling was activated.

It is a remarkable event that the PGD~2~-induced augmentation of contraction was inhibited by laropiprant, an antagonist of DP~1~ receptor that is known as a Gs protein-coupled receptor. In smooth muscle cells including the airways, the Gs protein activation, such as beta-adrenoceptor stimulation by isoprenaline, causes an increase in cAMP level to induce relaxation \[[@B25-ijms-19-03036],[@B26-ijms-19-03036],[@B27-ijms-19-03036]\]. However, the current study indicated that activation of DP~1~ receptor by PGD~2~ could cause a response to contractile direction. Although the discrepancy is not explainable now, an activation of extracellular signal-regulated kinase (ERK) signaling by DP~1~ receptor stimulation has also been reported in nasal epithelial cells \[[@B28-ijms-19-03036]\]. It is thus possible that, in addition to the classical Gs/cAMP pathway, the DP~1~ receptor stimulation activates multiple intracellular signaling, including the RhoA/Rho-kinase signaling. Further studies are needed to make clear the mechanism of action of PGD~2~ in the BSMs.

In conclusion, the current study revealed that PGD~2~ augmented the BSM contraction by activating the RhoA/Rho-kinase-mediated Ca^2+^ sensitization of contraction via an activation of DP~1~ receptors on the BSM cells. Increased PGD~2~ level in the airways might be one of the causes of the enhanced airway responsiveness to nonspecific stimuli, one of the characteristic features of bronchial asthma.

4. Materials and Methods {#sec4-ijms-19-03036}
========================

4.1. Animals {#sec4dot1-ijms-19-03036}
------------

Male BALB/c mice were purchased from the Tokyo Laboratory Animals Science Co., Ltd. (Tokyo, Japan) and housed in a pathogen-free facility. All animal experiments were approved by the Animal Care Committee of the Hoshi University, Tokyo, Japan (permission code: 30-086, permission date: 21 June 2018).

4.2. Pharmacological Reagents {#sec4dot2-ijms-19-03036}
-----------------------------

Prostaglandin D~2~ (PGD~2~: Cat. No. 12010) and laropiprant (MK-0524: Cat. No. 10009835) were purchased from Cayman Chemical (Ann Arbor, MI, USA). Fevipiprant was purchased from MedChem Express (Monmouth Junction, NJ, USA: Cat. No. HY-16768).

4.3. Determination of Bronchial Smooth Muscle (BSM) Responsiveness {#sec4dot3-ijms-19-03036}
------------------------------------------------------------------

Mice were sacrificed by exsanguination from abdominal aorta under urethane (1.6 g/kg, *i.p.*) anesthesia and the airway tissues under the larynx to lungs were immediately removed. About 3 mm length of the left main bronchus (about 0.5 mm diameter) was isolated. The resultant tissue ring preparation was then suspended in a 5 mL organ bath by two stainless-steel wires (0.2 mm diameter) passed through the lumen. For all tissues, one end was fixed to the bottom of the organ bath while the other was connected to a force-displacement transducer (TB-612T, Nihon Kohden, Tokyo, Japan) for the measurement of isometric force. A resting tension of 0.5 g was applied. The buffer solution contained modified Krebs--Henseleit solution with the following composition (mM): NaCl 118.0, KCl 4.7, CaCl~2~ 2.5, MgSO~4~ 1.2, NaHCO~3~ 25.0, KH~2~PO~4~ 1.2, and glucose 10.0. The buffer solution was maintained at 37 °C and oxygenated with 95% O~2~/5% CO~2~. After the equilibration period, the tension studies were performed. In case of the high K^+^ depolarization studies, experiments were conducted in the presence of atropine (10^−6^ M).

4.4. Determination of Active Form of RhoA in BSM {#sec4dot4-ijms-19-03036}
------------------------------------------------

The active form of RhoA, GTP-bound RhoA, in BSMs was measured by GTP-RhoA pull-down assay as described previously \[[@B19-ijms-19-03036]\]. In brief, the isolated main bronchial tissues were equilibrated in oxygenated Krebs--Henseleit solution at 37 °C for 1 h. After the equilibration period, the tissues were stimulated with PGD~2~ (10^−5^ M) or ACh (10^−3^ M) for 15 min, and were quickly frozen with liquid nitrogen. The tissues were then lysed in lysis buffer with the following composition (mM): HEPES 25.0 (pH 7.5), NaCl 150, IGEPAL CA-630 1%, MgCl~2~ 10.0, EDTA 1.0, glycerol 10%, 1× protease inhibitor cocktail (Nakalai tesque, Kyoto, Japan), and 1× phosphatease inhibitor cocktail (Nakalai tesque). Active RhoA in tissue lysates (200 µg protein) was precipitated with 25 µg GST-tagged Rho binding domain (amino acids residues 7--89 of mouse rhotekin; Upstate, Lake Placid, NY, USA), which was expressed in *Escherichia coli* and bound to glutathione-agarose beads. The precipitates were washed three times in lysis buffer, and after adding the SDS loading buffer and boiling for 5 min, the bound proteins were resolved in 15% polyacrylamide gels, transferred to nitrocellulose membranes, and immunoblotted with rabbit polyclonal anti-RhoA (Abcam, Cambridge, UK) as primary antibodies.

4.5. Cell Culture and \[Ca^2+^\]~cyto~ Measurement {#sec4dot5-ijms-19-03036}
--------------------------------------------------

Normal human BSM cells (hBSMCs; a male donor: purchased from Cambrex Bio Science Walkersville, Inc., Walkersville, MD, USA) were maintained in SmBM medium (Cambrex Bio Science Walkersville, Inc., Walkersville, MD, USA) supplemented with 5% fetal bovine serum, 0.5 ng/mL human epidermal growth factor (hEGF), 5 µg/mL insulin, 2 ng/mL human fibroblast growth factor-basic (hFGF-b), 50 µg/mL gentamicin, and 50 ng/mL amphotericin B. Cells were maintained at 37 °C in a humidified atmosphere (5% CO~2~), fed every 48--72 h, and passaged when cells reached 90--95% confluence. Then the hBSMCs (passages 5--7) were seeded in 24-well plates (Becton Dickinson Labware, Franklin Lakes, NJ, USA) and were cultured without serum. Twenty-four hours after the starvation period, the cells were loaded with Fluo-8/AM (2.5 M: AAT Bioquest, Inc., Sunnyvale, CA, USA) in serum-free SmBM medium for 90 min at 37 °C. The cells were washed with PBS and maintained in Krebs--Henseleit solution described above. The intracellular Fluo-8 fluorescence was monitored using fluorescence microscope (Keyence, Osaka, Japan) with BZ-X filter GFP (470/40, 535/50 nm). Images were pictured using time-lapse imaging (Keyence), and analyzed with BZ-X analyzer (Keyence). Change in the cytosolic Ca^2+^ level was calculated as ratio to the basal fluorescence intensity.

4.6. RT-PCR Analyses {#sec4dot6-ijms-19-03036}
--------------------

Total RNAs of hBSMCs and mouse BSM tissues were extracted using NucleoSpin™ miRNA (TaKaRa Bio, Inc., Shiga, Japan) according to the manufacturer's instruction. cDNAs were prepared from the total RNA by using PrimeScript™ RT reagent Kit (TaKaRa) according to the manufacturer's instructions. cDNA samples were subjected to PCR with Quick Taq™ HS DyeMix (TOYOBO Co., Ltd., Osaka, Japan) in a final volume of 10 µL. The PCR primer sets used are shown in [Table 1](#ijms-19-03036-t001){ref-type="table"} (for human) and [Table 2](#ijms-19-03036-t002){ref-type="table"} (for mouse), which was designed from published database, BLAST. The thermal cycle profile used was (1) denaturing for 30 s at 94 °C, (2) annealing primers for 30 s at 60 °C, (3) extending the primers for 1 min at 68 °C, and the reaction was run for 40 cycles. The PCR products were subjected to electrophoresis on 2% agarose gel and visualized by ethidium bromide staining.

4.7. Statistical Analyses {#sec4dot7-ijms-19-03036}
-------------------------

All the data are expressed as means ± SE. Statistical significance of difference was determined by paired *t*-test ([Figure 2](#ijms-19-03036-f002){ref-type="fig"}B,C) or one-way analysis of variance (ANOVA) with post hoc Bonferroni's multiple comparison ([Figure 3](#ijms-19-03036-f003){ref-type="fig"}B and [Figure 4](#ijms-19-03036-f004){ref-type="fig"}C) using Prism 5 for Mac OS X (GraphPad Software, La Jolla, CA, USA). A value of *p* \< 0.05 was considered significant.

We thank Sayaka Endo, Mifuyu Shioda, Misaki Tsuchiyama, Shigeki Fujii, Yamato Yamane, and Yuki Kai for their technical assistance.

Conception and design, W.S. and Y.C.; analysis and interpretation, W.S., Y.A., T.H., F.T., and Y.C.; drafting the manuscript for important intellectual content: W.S., S.S., J.K., H.S., and Y.C. All authors read and approved the final manuscript.

This work was partly supported by Grant-in-Aid for Scientific Research (C) Grant Number 15K08248 (Y.C.) from the Japan Society for the Promotion of Science (JSPS).

The authors declare no conflict of interest.

ACh

acetylcholine

AHR

airway hyperresponsiveness

ANOVA

analysis of variance

BAL

bronchoalveolar lavage

BSM

bronchial smooth muscle

COX

cyclooxygenase

CRTH2

chemoattractant receptor-homologous molecule on Th2 cells

ERK

extracellular signal-regulated kinase

F

Ca

normalized ratios of the Ca

2+

fluorescence intensities

F

/

F

0

ratio of the Ca

2+

fluorescence intensity to that at time 0 (baseline)

Fluo-8/AM

Fluo-8 acetoxymethyl ester

GPCR

G protein-coupled receptor

GST

glutathione S-transferase

GTP

guanosine triphosphate

PG

prostaglandin

SDS

sodium dodecyl sulfate

TXA

2

thromboxane A

2

![Expression of various prostanoid receptors in cultured human bronchial smooth muscle (BSM) cells (**A**) and murine BSMs (**B**) determined by RT-PCR analyses. Marker: M.W. markers (100 bp ladder), GAPDH: glyceraldehyde-3-phosphate dehydrogenase, DP~1~: prostaglandin D~2~ (PGD~2~) receptor 1, DP~2~: PGD~2~ receptor 2, EP~1~: PGE~2~ receptor 1, EP~2~: PGE~2~ receptor 2, EP~3~: PGE~2~ receptor 3, EP~4~: PGE~2~ receptor 4, FP: PGF~2~ receptor, IP: PGI~2~ receptor, and TP: thromboxane A~2~ receptor. The primer sets used are shown in Materials and Methods section.](ijms-19-03036-g001){#ijms-19-03036-f001}

![Effects of prostaglandin D~2~ (PGD~2~) on the contraction induced by 30 mM K^+^ depolarization in bronchial smooth muscles (BSMs) isolated from mice. PGD~2~ (10^−9^--10^−5^ M) had no effect on basal tone (**A**). After the stable contraction induced by K^+^ depolarization was observed, 10^−6^ (**B**) or 10^−5^ M (**C**) PGD~2~ was applied. Representative traces of changes in the active force are shown in respective upper panels, and the data are summarized in the lower panels. Results are presented as mean ± SEM from 5 animals, respectively. \* *p* \< 0.05 and \*\*\* *p* \< 0.001 versus without PGD~2~ by paired Student's *t*-test.](ijms-19-03036-g002){#ijms-19-03036-f002}

![Effect of laropiprant (a selective DP~1~ receptor antagonist) on the augmented contraction induced by prostaglandin D~2~ (PGD~2~) in bronchial smooth muscles (BSMs) isolated from mice. After the BSM contraction induced by PGD~2~ reached to plateau, 10^−6^ M laropiprant was applied. Representative traces of changes in the active force are shown in (**A**), and the data are summarized in (**B**). Results are presented as mean ± SEM from 5 animals. \*\*\* *p* \< 0.001 versus 30 mM K^+^ only group and ^††^ *p* \< 0.01 versus 30 mM K^+^ + 10^−5^ M PGD~2~ group by one-way ANOVA with post hoc Bonferroni's multiple comparison. Note that fevipiprant (10^−6^ M, a selective DP~2~ receptor antagonist) had no effect on the PGD~2~-induced augmentation of contraction (**C**).](ijms-19-03036-g003){#ijms-19-03036-f003}

![Effects of prostaglandin D~2~ (PGD~2~) on the cytosolic Ca^2+^ level in cultured human bronchial smooth muscle cells (hBSMCs) determined by a fluorescent Ca^2+^ indicator Fluo-8. (**A**,**B**) Representative trace of change in cytosolic Ca^2+^ (*F*/*F*~0~, ratio of the Ca^2+^ fluorescence intensity to that at time 0 (baseline)). The Fluo-8-loaded hBSMCs were stimulated with 30 mM K^+^ and, when its stable response was observed, 10^−5^ M PGD~2~ was applied. To confirm the maximal response, a Ca^2+^ ionophore A23187 (10^−5^ M) was applied at the end of experiments. (**C**) Summary of normalized ratios of the Ca^2+^ fluorescence intensities (*F*~Ca~) data. Results are presented as mean ± SEM from 8 independent experiments. Note that neither the baseline Ca^2+^ level nor the stable increase in Ca^2+^ induced by K^+^ depolarization was affected by PGD~2~.](ijms-19-03036-g004){#ijms-19-03036-f004}

![Activation of RhoA/Rho-kinase signaling by prostaglandin D~2~ (PGD~2~) in bronchial smooth muscle (BSM) of the mouse. (**A**) Effect of PGD~2~ on the level of GTP-bound active form of RhoA. Freshly isolated BSMs of mice were stimulated with acetylcholine (ACh: 10^−3^ M) or PGD~2~ (10^−5^ M) for 10 min, and GTP-RhoA pull-down assay and RhoA immunoblottings were performed as described in Materials and Methods section. The blots for GTP-bound (active: *upper*) and total RhoA (*lower*) are shown and representative from 3 independent experiments, respectively. (**B**) Effect of Y-27632 (a selective Rho-kinase inhibitor) on the augmented contraction induced by prostaglandin D~2~ (PGD~2~) in BSMs isolated from mice. After the BSM contraction induced by PGD~2~ reached to plateau, 10^−7^ M Y-27632 was applied. A trace of change in the active force is shown and representative from 3 independent experiments.](ijms-19-03036-g005){#ijms-19-03036-f005}

ijms-19-03036-t001_Table 1

###### 

Primer sequences for RT-PCR used in the present study (human).

  Gene Name        RefSeq Accession                         Sequence                               Amplicon Size
  ---------------- -------------------------------- ------- -------------------------------------- ---------------
  human *PTGDR*    NM_000953                        Sense   5′-TCTGCGCGCTACCTTTCATG-3′             85 bp
  Antisense        5′-TCCTCGTGGACCATCTGGATA-3′                                                     
  human *PTGDR2*   NM_004778                        Sense   5′-CCTCTGTGCCCAGAGCCCCACGATGTCGGC-3′   114 bp
  Antisense        5′-ATGTAGCGGATGCTGGTGTTG-3′                                                     
  human *PTGER1*   NM_000955                        Sense   5′-GATGGTGGGCCAGCTTGTC-3′              72 bp
  Antisense        5′-GCCACCAACACCAGCATTG-3′                                                       
  human *PTGER2*   NM_000956                        Sense   5′-GTGCTGACAAGGCACTTCATGT-3′           87 bp
  Antisense        5′-TGTTCCTCCAAAGGCCAAGTAC-3′                                                    
  human *PTGER3*   NM_198714                        Sense   5′-AAGGCCACGGCATCTCAGT-3′              76 bp
  Antisense        5′-TGATCCCCATAAGCTGAATGG-3′                                                     
  human *PTGER4*   NM_000958                        Sense   5′-CTTGGAGGCAGGAATTTGCTT-3′            77 bp
  Antisense        5′-AAAGTCCTCAGTGAGGTGGTGTCT-3′                                                  
  human *PTGFR*    NM_000959                        Sense   5′-GCACATTGATGGGCAACTAGAA-3′           91 bp
  Antisense        5′-GCACCTATCATTGGCATGTAGCT-3′                                                   
  human *PTGIR*    NM_000960                        Sense   5′-GCCGATCAGCTGCTGTTTCT-3′             75 bp
  Antisense        5′-TTTCCTCTGTCCCTCACTCTCTTC-3′                                                  
  human *TBXA2R*   NM_001060                        Sense   5′-ACGGAGAAGGAGCTGCTCATC-3′            84 bp
  Antisense        5′-GCGGCGGAACAGGATATACA-3′                                                      
  human *GAPDH*    NM_002046                        Sense   5′-GGAGCCAAAAGGGTCATCATCTC-3′          282 bp
  Antisense        5′-AGGGATGATGTTCTGGAGAGCC-3′                                                    

ijms-19-03036-t002_Table 2

###### 

Primer sequences for RT-PCR used in the present study (mouse).

  Gene Name        RefSeq Accession                         Sequence                           Amplicon Size
  ---------------- -------------------------------- ------- ---------------------------------- ---------------
  mouse *Ptgdr1*   NM_008962                        Sense   5′-CAACCTGGGTGCCATGTAC-3′          112 bp
  Antisense        5′-GGACCCGTGCCTGTAGTCT-3′                                                   
  mouse *Ptgdr2*   NM_009962                        Sense   5′-CTGCACCTGGCGCTATC-3′            174 bp
  Antisense        5′-GTCCAGGCTAATGGCACT-3′                                                    
  mouse *Ptger1*   NM_013641                        Sense   5′-TACATGGGATGCTCGAAACA-3′         223 bp
  Antisense        5′-TTTTAGGCCGTGTGGGTAG-3′                                                   
  mouse *Ptger2*   NM_008964                        Sense   5′-ATGCACCTGCTGCTTATCGT-3′         196 bp
  Antisense        5′-TAATGGCCAGGAGAATGAGG-3′                                                  
  mouse *Ptger3*   NM_001359745                     Sense   5′-TGCTGGCTCTGGTGGTGAC-3′          258 bp
  Antisense        5′-ACTCCTTCTCCTTTCCCATCTGTG-3′                                              
  mouse *Ptger4*   NM_001136079                     Sense   5′-CCATCGCCACATACATGAAG-3′         209 bp
  Antisense        5′-TGCACAGATGGCGAAGAGTG-3′                                                  
  mouse *Ptgfr*    NM_008966                        Sense   5′-CTGCTCCGGACACAACCACTC-3′        191 bp
  Antisense        5′-GGTTCTCCGTCTGGCAGGTTG-3′                                                 
  mouse *Ptgir*    NM_008967                        Sense   5′-GGATGAAGTTTACCACCTGATTCTGC-3′   196 bp
  Antisense        5′-AGCCTTTCGGAAAAGGATGAAGAC-3′                                              
  mouse *Tbxa2r*   NM_009325                        Sense   5′-TTTCGCCCGGTGAACATC-3′           255 bp
  Antisense        5′-GGCTCGCCAGTCCAACAA-3′                                                    
  mouse *Gapdh*    NM_001289726                     Sense   5′-CCTCGTCCCGTAGACAAAATG-3′        100 bp
  Antisense        5′-TCTCCACTTTGCCACTGCAA-3′                                                  
